Conclusions -Interleukin S is detectable in the serum ofa proportion ofboth atopic and non-atopic patients with chronic severe asthma, and concentrations in these patients were higher than in normal controls. These observations are compatible with the hypothesis that IL-5 release occurs in these patients during a period of stable asthma despite systemic glucocorticoid therapy.
We have previously shown that peripheral blood CD4 T lymphocyte activation is accompanied by raised serum concentrations of IL-5 in a proportion of both atopic and nonatopic patients with acute severe asthma, but that IL-5 was not detectable in the same patients following oral glucocorticoid therapy, or in normal controls.4 Others have reported raised plasma concentrations of soluble IL-2 receptor in oral glucocorticoid-dependent asthmatics compared with patients controlled without oral glucocorticoids, suggesting that ongoing T lymphocyte activation is associated with severe chronic disease despite maintenance prednisolone.5 The aim of this study was to investigate whether IL-5 may be implicated in the pathogenesis of oral glucocorticoid-dependent chronic severe asthma. Methods Documented chronic asthmatic subjects aged 18-65 years with FEV, and/or PEFR below 75% of the predicted value and >20% reversibility to f2 agonist were considered for the study if they required long term maintenance treatment with 5-20 mg oral prednisolone daily, in addition to maximal tolerated and effective other therapy including high dose inhaled glucocorticoids. Written informed consent was obtained from each patient and the study was approved by the ethics committee of the Royal Brompton National Heart and Lung Hospitals.
A total of 1 1 men and 18 women aged 21-62 (mean 49) years who had had asthma for 5-54 (mean 29) years and had received continuous treatment with oral prednisolone for 0-5-26 (mean 9 7) years were enrolled. Mean (SE) daily dosage of prednisolone was 8-6 (0 8) mg and of inhaled glucocorticoid was 1630 (99) jg; median (range) total serum IgE concentration was 76 (6-1250) IU/ml and peripheral blood eosinophil count 0-2 (0-1 2) x 109/1. Twenty of the patients studied were atopic (as defined by one or more positive skin prick tests to with oral theophylline. A group of seven normal healthy volunteers aged 21-46 (mean 30) years with no known diseases and taking no medication was also studied. Mean (SE) FEV, was 100 (2-7)% predicted and three subjects were atopic.
Patients recorded PEFR measurements on diary cards at home during a four week period. Those who had a disease exacerbation requiring an increase in prednisolone dosage were excluded, ensuring that all patients had been stable on their usual maintenance prednisolone dosage during the four week study period. At the end of this period FEV, was measured in the clinic and a peripheral venous blood sample was obtained for measurement of whole blood eosinophil count and serum IL-5 concentration. Mean 
